Barinthus Biotherapeutics (BRNS) Competitors

$0.68 +0.05 (+7.05%)

Closing price 05/19/2026 04:00 PM Eastern

Extended Trading

$0.69 +0.00 (+0.51%)

As of 04:04 AM Eastern

BRNS vs. KALA, ONCY, ALDX, ANIX, and ATYR

Should you buy Barinthus Biotherapeutics stock or one of its competitors? MarketBeat compares Barinthus Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Barinthus Biotherapeutics include KALA BIO (KALA), Oncolytics Biotech (ONCY), Aldeyra Therapeutics (ALDX), Anixa Biosciences (ANIX), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry.

How does Barinthus Biotherapeutics compare to KALA BIO?

Barinthus Biotherapeutics (NASDAQ:BRNS) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 485.22%. KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 40,166.80%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, KALA BIO had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for KALA BIO and 0 mentions for Barinthus Biotherapeutics. KALA BIO's average media sentiment score of 1.21 beat Barinthus Biotherapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
KALA BIO	Positive

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

KALA BIO has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.87	-$66.43M	-$1.29	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Barinthus Biotherapeutics has a beta of -0.43, meaning that its stock price is 143% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.23, meaning that its stock price is 323% less volatile than the broader market.

Barinthus Biotherapeutics' return on equity of -63.83% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

Barinthus Biotherapeutics beats KALA BIO on 7 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncolytics Biotech has lower revenue, but higher earnings than Barinthus Biotherapeutics. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.87	-$66.43M	-$1.29	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 485.22%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 996.77%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Barinthus Biotherapeutics' return on equity of -63.83% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Oncolytics Biotech	N/A	-14,442.84%	-321.54%

In the previous week, Oncolytics Biotech had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.00 beat Oncolytics Biotech's score of -1.67 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Oncolytics Biotech	Very Negative

Barinthus Biotherapeutics has a beta of -0.43, indicating that its share price is 143% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

Summary

Oncolytics Biotech beats Barinthus Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Aldeyra Therapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Aldeyra Therapeutics had 22 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 22 mentions for Aldeyra Therapeutics and 0 mentions for Barinthus Biotherapeutics. Aldeyra Therapeutics' average media sentiment score of 0.05 beat Barinthus Biotherapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Aldeyra Therapeutics	Neutral

Barinthus Biotherapeutics has a beta of -0.43, indicating that its stock price is 143% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.87	-$66.43M	-$1.29	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 485.22%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 256.22%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics' return on equity of -57.34% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Aldeyra Therapeutics beats Barinthus Biotherapeutics on 9 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Anixa Biosciences?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Barinthus Biotherapeutics' return on equity of -63.83% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Anixa Biosciences	N/A	-70.95%	-62.53%

In the previous week, Anixa Biosciences had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Anixa Biosciences and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Anixa Biosciences	Neutral

Anixa Biosciences has lower revenue, but higher earnings than Barinthus Biotherapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.87	-$66.43M	-$1.29	N/A
Anixa Biosciences	$210K	426.31	-$10.93M	-$0.33	N/A

Barinthus Biotherapeutics has a beta of -0.43, indicating that its share price is 143% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 485.22%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 218.35%. Given Barinthus Biotherapeutics' higher possible upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Anixa Biosciences beats Barinthus Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

aTyr Pharma currently has a consensus price target of $25.67, indicating a potential upside of 5,214.01%. Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 485.22%. Given aTyr Pharma's higher possible upside, equities research analysts plainly believe aTyr Pharma is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics' return on equity of -63.83% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

In the previous week, aTyr Pharma had 9 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 9 mentions for aTyr Pharma and 0 mentions for Barinthus Biotherapeutics. aTyr Pharma's average media sentiment score of 0.38 beat Barinthus Biotherapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Neutral
Barinthus Biotherapeutics	Neutral

aTyr Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.43, indicating that its stock price is 143% less volatile than the broader market.

Barinthus Biotherapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	249.25	-$74.12M	-$0.73	N/A
Barinthus Biotherapeutics	$14.97M	1.87	-$66.43M	-$1.29	N/A

Summary

aTyr Pharma beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.08M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-0.53	18.52	20.79	25.05
Price / Sales	1.87	270.32	536.87	72.66
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	0.42	6.60	9.79	6.83
Net Income	-$66.43M	$24.18M	$3.55B	$335.69M
7 Day Performance	0.07%	-3.74%	-2.13%	-2.15%
1 Month Performance	15.85%	-7.95%	-4.16%	-2.47%
1 Year Performance	-23.20%	50.32%	28.31%	27.13%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	2.1222 of 5 stars	$0.68 +7.0%	$4.00 +485.2%	-19.6%	$26.08M	$14.97M	N/A	107	Gap Up
KALA KALA BIO	2.3244 of 5 stars	$0.12 +2.7%	$20.38 +17,602.0%	-98.6%	$106.98M	N/A	N/A	30	Positive News Earnings Report Gap Up
ONCY Oncolytics Biotech	2.581 of 5 stars	$0.92 +0.5%	$8.50 +823.9%	+74.3%	$106.84M	N/A	N/A	30	Negative News Earnings Report
ALDX Aldeyra Therapeutics	3.036 of 5 stars	$1.74 +1.2%	$5.50 +216.1%	-36.2%	$104.96M	N/A	N/A	10	Trending News
ANIX Anixa Biosciences	1.8463 of 5 stars	$3.06 +2.0%	$8.50 +177.8%	-1.1%	$102.60M	$210K	N/A	5	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. KALA, ONCY, ALDX, ANIX, and ATYR

How does Barinthus Biotherapeutics compare to KALA BIO?

Summary

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Summary

How does Barinthus Biotherapeutics compare to Aldeyra Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Anixa Biosciences?

Summary

How does Barinthus Biotherapeutics compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. KALA, ONCY, ALDX, ANIX, and ATYR

How does Barinthus Biotherapeutics compare to KALA BIO?

Do analysts rate BRNS or KALA?

Does the media refer more to BRNS or KALA?

Do institutionals & insiders hold more shares of BRNS or KALA?

Which has stronger earnings & valuation, BRNS or KALA?

Which has more risk & volatility, BRNS or KALA?

Is BRNS or KALA more profitable?

Summary

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Do insiders and institutionals have more ownership in BRNS or ONCY?

Which has stronger earnings and valuation, BRNS or ONCY?

Do analysts prefer BRNS or ONCY?

Is BRNS or ONCY more profitable?

Does the media refer more to BRNS or ONCY?

Which has more risk & volatility, BRNS or ONCY?

Summary

How does Barinthus Biotherapeutics compare to Aldeyra Therapeutics?

Does the media refer more to BRNS or ALDX?

Which has more volatility & risk, BRNS or ALDX?

Which has better valuation and earnings, BRNS or ALDX?

Do institutionals & insiders have more ownership in BRNS or ALDX?

Do analysts prefer BRNS or ALDX?

Is BRNS or ALDX more profitable?

Summary

How does Barinthus Biotherapeutics compare to Anixa Biosciences?

Is BRNS or ANIX more profitable?

Does the media prefer BRNS or ANIX?

Which has stronger valuation & earnings, BRNS or ANIX?

Which has more risk & volatility, BRNS or ANIX?

Do insiders and institutionals have more ownership in BRNS or ANIX?

Do analysts prefer BRNS or ANIX?

Summary

How does Barinthus Biotherapeutics compare to aTyr Pharma?

Do institutionals and insiders hold more shares of ATYR or BRNS?

Do analysts rate ATYR or BRNS?

Is ATYR or BRNS more profitable?

Does the media prefer ATYR or BRNS?

Which has more risk and volatility, ATYR or BRNS?

Which has better valuation & earnings, ATYR or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools